-
Published on 23 Feb 2017
NetScientific PLC (LON:NSCI) boss François Martelet talks Proactive through news its
flagship company Vortex Biosciences has begun the commercial launch of
its VTX1 Liquid Biopsy system.
It's the first time Netscientific has been able to market a cancer diagnostic instrument and it has been executed on time and in line with market expectations, he says.
It's the first time Netscientific has been able to market a cancer diagnostic instrument and it has been executed on time and in line with market expectations, he says.
"It's a very fast and simple way to isolate and collect intact CTCs directly from the whole blood," he says.
No comments:
Post a Comment